Current Treatment Options in Oncology

, Volume 15, Issue 1, pp 14–26 | Cite as

Appropriate Use of Complementary and Alternative Medicine Approaches in Gynecologic Cancers

  • Dana M. Chase
  • Steven J. Gibson
  • Daniele A. Sumner
  • Jennifer W. Bea
  • David S. Alberts
Gynecologic Cancers (RJ Morgan, Section Editor)

Opinion statement

Gynecologic cancer patients frequently desire alternative and/or complementary interventions or medicines to aid in relief of both cancer-related and treatment-related side effects. Furthermore, women also seek treatment to aid in superior outcomes and cure rates. Unfortunately, evidence suggests that the use of complementary and/or alternative medicine (CAM) is underreported or not discussed with physicians providing cancer care. In gynecologic cancer literature, there is a lack of scientific evidence either supporting or negating CAM. Because of the lack of information available, health care providers do not have good information regarding safety, efficacy, and dose of CAM. This leads to miscommunication or absence of communication between providers and patients. Because patients do use CAM to improve quality of life (QOL) during and after treatment, it would be educational for providers to know the specific QOL deficits among patients that require attention. Thus, with the ultimate goal of improving QOL for gynecologic cancer patients, providers should be pushed to investigate CAM and determine an honest support or rejection of these therapies.

Keywords

Complementary medicine Alternative medicine Gynecologic cancer Ovarian cancer Cervical cancer 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    National Institutes of Health: National Center for Complementary and Alternative Medicine (NCCAM). Available at: http://nccam.nih.gov/health/whatiscam. Accessed September 23, 2013.
  2. 2.
    American Cancer Society. Available at: http://www.cancer.org. Accessed September 23, 2013.
  3. 3.
    Matulonis UA, Kornblith A, Lee H, et al. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008;18:1183–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Von Gruenigen VE, Frasure HE, Jenison EL, et al. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol. 2006;103:120–6.CrossRefGoogle Scholar
  5. 5.
    Ferrell B, Smith S, Cullinane C, et al. Symptom concerns of women with ovarian cancer. J Pain Symptom Manag. 2003;25:528–38.CrossRefGoogle Scholar
  6. 6.
    Nahin RL, Barnes PM, Stussman BJ, et al. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report. 2009;18:1–14.PubMedGoogle Scholar
  7. 7.
    Rhode JM, Patel DA, Sen A, et al. Perception and use of complementary and alternative medicine among gynecologic oncology care providers. Int J Gynaecol Obstet. 2008;203:111–5.CrossRefGoogle Scholar
  8. 8.
    Downey L, Tyree PT, Lafferty WE. Preventive screening of women who use complementary and alternative medicine providers. J Womens Health. 2009;18:1133–43.CrossRefGoogle Scholar
  9. 9.
    Navo MA, Phan J, Vaughan C, et al. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol. 2004;22:671–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Pineda MJ, Singh DK. What is integrative oncology and can it help my patients? Obstet Gynecol Clin North Am. 2012;39:285–312.PubMedCrossRefGoogle Scholar
  11. 11.
    Lopez AJ, McCaffrey R, Quinn Griffin MT, et al. Spiritual well-being and practices among women with gynecologic cancer. Oncol Nurs Forum. 2009;36:300–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Greenwald HP, McCorkle R. Remedies and life changes among invasive cervical cancer survivors. Urol Nurs. 2007;27:47–53.PubMedGoogle Scholar
  13. 13.
    Smith AR, DeSanto-Madeya S, Perez JE, et al. How women with advanced cancer pray: a report from two focus groups. Oncol Nurs Forum. 2012;39:E310–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Leon-Pizarro C, Gich I, Barthe E, et al. A randomized trial of the effect of training in relaxation and guided imagery techniques in improving psychological and quality-of-life indices for gynecologic and breast brachytherapy patients. Psychooncology. 2007;16:971–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Brotto LA, Erskine Y, Carey M, et al. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning vs wait-list control in women treated for gynecologic cancer. Gynecol Oncol. 2012;125:320–5.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Kwekkeboom KL, Abbott-Anderson K, Wanta B. Feasibility of a patient-controlled cognitive-behavioral intervention for pain, fatigue, and sleep disturbance in cancer. Oncol Nurs Forum. 2010;37:E151–9.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Lutgendorf SK, Mullen-Houser E, Russel D, et al. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immune. 2010;24:1231–40.CrossRefGoogle Scholar
  18. 18.
    Chan YM, Lee PW, Ng TY, et al. The use of music to reduce anxiety for patients undergoing colposcopy: a randomized trial. Gynecol Oncol. 2003;91:213–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Sanchez-Ledesma MJ, Lopez-Olaondo L, Pueyo FJ, et al. A comparison of three antiemetic combinations for the prevention of postoperative nausea and vomiting. Anesth Analg. 2002;95:1590–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Turgut S, Ozalp G, Dikmen S, et al. Acupressure for postoperative nausea and vomiting in gynaecological patients receiving patient-controlled analgesia. Eur J Anaesthesiol. 2007;24:87–91.PubMedCrossRefGoogle Scholar
  21. 21.
    Matulonis U, Campos S, Duska L, et al. A phase II trial of three sequential doublets for the treatment of advanced mullerian malignancies. Gynecol Oncol. 2003;91:293–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Lu W, Matulonis UA, Doherty-Gilman A, et al. Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med. 2009;15:745–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Mitchell JL, Walsh J, Wang-Cheng R, et al. Postmenopausal hormone therapy: a concise guide to therapeutic uses, formulations, risks, and alternatives. Prim Care. 2003;30:671–96.PubMedCrossRefGoogle Scholar
  24. 24.
    Gavronsky S, Koeniger-Donohue R, Steller J, et al. Postoperative pain: acupuncture vs percutaneous electrical nerve stimulation. Pain Manage Nurs. 2012;13:150–6.CrossRefGoogle Scholar
  25. 25.•
    Sweet ES, Standish LJ, Goff BA, et al. Adverse events associated with complementary and alternative medicine use in ovarian cancer patients. Integr Cancer Ther. 2013;12:508–16. This study found the current literature on drug-CAM interactions to be limited, raising concerns about CAM-chemotherapy interactions and its impact on anticipated treatment outcomes given the high percentage of CAM use in ovarian cancer patients.Google Scholar
  26. 26.
    Manusirivithaya S, Sripramote M, Tangjitgamol S, et al. Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer. 2004;14:1063–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Ye B, Aponte M, Dai Y, et al. Ginkgo Biloba and ovarian cancer prevention: epidemiological and biological evidence. Cancer Lett. 2007;251:43–52.PubMedCrossRefGoogle Scholar
  28. 28.
    Rees M. Gynaecological oncology perspective on management of the menopause. Eur J Surg Oncol. 2006;32:892–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Klein A, He X, Roche M, et al. Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy. Gynecol Oncol. 2006;100:205–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Fasching PA, Thiel F, Nicolaisen-Murmann K, et al. Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. Support Care Cancer. 2007;15:1277–84.PubMedCrossRefGoogle Scholar
  31. 31.
    Chan KK, Yao TJ, Jones B, et al. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol. 2011;22:2241–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Del Priore G, Gudipudi DK, Montemarano N, et al. Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol Oncol. 2010;116:464–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Powell CB, Fung P, Jackson J, et al. Aqueous extract of herba Scutellaria barbatea, a Chinese herb used for ovarian cancer, induced apoptosis of ovarian cancer cell lines. Gynecol Oncol. 2003;91:332–40.PubMedCrossRefGoogle Scholar
  34. 34.
    Zhu K, Fukasawa I, Furuno M, et al. Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis. Gynecol Oncol. 2005;97:405–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Drisko JA, Chapman J, Hunter VJ. The use of antioxidant therapies during chemotherapy. Gynecol Oncol. 2003;88:434–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Cruciani RA, Zhang JJ, Manola J, et al. L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2012;30:3864–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Hershman DL, Unger JM, Crew KD, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol. 2013;31:2627–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Newton MJ, Hayes SC, Janda M, et al. Safety, feasibility and effects of an individualized walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study. BCM Cancer. 2011;11:389.Google Scholar
  39. 39.••
    Becker H, Jung S. Health promotion among older cancer survivors with prior disabling conditions. J Gerontol Nurs. 2012;38:38–43. This study demonstrated the benefit of exercise intervention in cancer treatment to reduce symptoms and increase QOL, supporting other recent studies (ie, LIvES) that are examining the role exercise can play as CAM in cancer treatment.Google Scholar
  40. 40.
    Prentice RL, Thomson CA, Caan BJ, et al. Low-fat dietary pattern and cancer incidence in the Women’s Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst. 2007;99:1534–43.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: The Iowa Women's Health Study. Cancer. 2004;100:1515–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Dana M. Chase
    • 1
  • Steven J. Gibson
    • 1
  • Daniele A. Sumner
    • 1
  • Jennifer W. Bea
    • 2
  • David S. Alberts
    • 2
  1. 1.Division of Gynecologic Oncology, Department of Obstetrics and GynecologyUniversity of Arizona Cancer Center, Creighton University School of Medicine at St. Joseph’s Hospital and Medical CenterPhoenixUSA
  2. 2.Department of Medicine, The University of Arizona Cancer CenterThe University of ArizonaTucsonUSA

Personalised recommendations